Nadroparin
- Generic Name
- Nadroparin
- Brand Names
- Fraxiparine
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- 1K5KDI46KZ
- Background
Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
- Indication
Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.
- Associated Conditions
- Clotting, Deep Vein Thrombosis, Pulmonary Embolism, Unstable Angina Pectoris, Venous Thromboembolism, Non-q wave myocardial infarction, Thromboembolic phenomena
The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT
- Conditions
- Portal Vein ThrombosisLiver Cirrhosis
- Interventions
- Device: Doppler ultrasound and CT
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT02630095
- Locations
- 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis
- Conditions
- AnticoagulationLiver CirrhosisPortal Vein Thrombosis
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Air Force Military Medical University, China
- Registration Number
- NCT02526303
The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis
- Conditions
- Liver CirrhosisPortal Vein Thrombosis
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT02398357
- Locations
- 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
Prophylaxis of Venous Thromboembolism After Bariatric Surgery
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Rijnstate Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02295150
- Locations
- 🇳🇱
Rijnstate Hospital, Arnhem, Wagnerlaan 55, Netherlands
Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- University Hospital, Martin
- Target Recruit Count
- 150
- Registration Number
- NCT01862978
- Locations
- 🇸🇰
Neurology Clinic Univeristy Hospital in Martin, Martin, Slovakia
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
- Conditions
- Pulmonary EmbolismDeep Venous Thrombosis
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2022-05-26
- Target Recruit Count
- 1110
- Registration Number
- NCT01828697
- Locations
- 🇫🇷
CHU de Besancon, Besançon, France
🇫🇷CHU de Brest, Brest, France
🇫🇷Marseille St Joseph, Marseille, France
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Martini Hospital Groningen
- Target Recruit Count
- 148
- Registration Number
- NCT01431456
- Locations
- 🇳🇱
Martini Ziekenhuis, Groningen, Netherlands
The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
- Conditions
- Lung NeoplasmsEsophageal NeoplasmsVenous Thromboembolism
- Interventions
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 362
- Registration Number
- NCT01267305
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
Heparin for Pregnant Women With Thrombophilia
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 300
- Registration Number
- NCT01019655
- Locations
- 🇦🇹
Department of Obstetrics and Gynecology, Vienna, Austria
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
- Conditions
- Advanced CancerMetastatic Cancer
- Interventions
- Drug: saline solution (placebo)
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 1166
- Registration Number
- NCT00951574
- Locations
- 🇮🇹
Salvatore Maugeri Foundation, Pavia, Italy
🇮🇹Hematology and Oncology Department, Piacenza, Italy
🇮🇹Medical Oncology Department Regina Elena Institute, Roma, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.